BCL2 and acute lymphoblastic leukemia: Treatment of TCF-HLF-positive B-ALL samples with venetoclax also resulted in the rapid reduction of tumor burden in a mouse xenograft model, linking the elevated expression of BCL-2 and sensitivity to its inhibition [10,18].